JV-DE1 / JeniVision - LARVOL DELTA

Discovery and Potential Utility of a Novel Non-Invasive Ocular Delivery Platform. (PubMed, Pharmaceutics) - "The NIODP also delivered JV-DE1, an anti-inflammatory agent in development for dry eye diseases, as efficiently as eye drops did to the anterior segments of the NHP...The novel NIODP method has the potential to reshape the landscape of ocular drug delivery. This is especially the case for oily eye drops and retinal delivery, where the success of the treatment lies in the ocular tolerability and bioavailability of drugs in the target tissue."

Journal • Age-related Macular Degeneration • Dry Eye Disease • Ocular Inflammation • Ophthalmology • Retinal Disorders